• About Us
  • Board of Advisors
  • Contact

MALARIA.com

A Malaria Information and Community Portal

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
Home / Malaria Q&A / Malaria Vaccine Research

Malaria Vaccine Research

March 9, 2012 By Malaria Q&A Leave a Comment

QUESTION

Is there any research to produce anti malaria vaccine, if not, why?

ANSWER

There are many teams of scientists working hard to try to produce a malaria vaccine. In fact, only last year, the preliminary results of a vaccine trial were published. The vaccine, called RTS,S, has been produced by GlaxoSmithKline and is in the midst of Phase III trials in Africa. The preliminary results showed approximately a 50% reduction in malaria incidence, though it is not clear how much of that protection came from the vaccine and how much should be attributed to the vaccine adjunct (a compound given with the vaccine to boost immune responses).

The preliminary results also did not include analysis of how much the vaccine prevented mortality due to malaria, and levels of protection against severe malaria appeared to be low. However, we will have to wait until 2014 for the full and final results of the clinical trial to be made available. In the meantime, other vaccine candidates are being developed, but there are many challenges to overcome.

For example, there are five different types of malaria that infect people: these differ significantly in the way they develop in the human host, and so a vaccine appropriate for one may not be effective against the others. Most vaccine researchers are focusing on Plasmodium falciparum, the most deadly form of malaria, and a vaccine effective against this parasite would certainly do the most to reduce malaria-related mortality. However, Plasmodium vivax also causes high morbidity, particularly in Asia and the Pacific, and so should not be overlooked.

Moreover, within each of these species exist different strains in different areas, each of which can be markedly different from a genetic perspective. Finally, we do not yet fully understand the complex ways in which our immune system reacts to malaria. As such, this presents a challenge to developing an effective malaria vaccine, though many scientists are willing to address this challenge and have made big inroads in the search for a safe, effective vaccine. For more information on current efforts to develop a malaria vaccine, please see PATH’s Malaria Vaccine Initiative.

Filed Under: Malaria Q&A Tagged With: GlaxoSmithKline, immune response variation, Malaria Control, malaria research, Malaria Vaccine Initiative, PATH, Phase III trial, Plasmodium, RTS, S, strain variation, vaccine

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Informed

WWARN Corner

About WWARN

The WorldWide Antimalarial Resistance Network (WWARN) generates innovative resources and reliable evidence to inform the malaria community on the factors affecting the efficacy of antimalarial medicines. Learn more…

  • Fighting Malaria Requires Protecting the Effectiveness of Antimalarial Medicines
  • Data Sharing at IDDO
  • Evidence to inform equitable dosing in very young and malnourished children

More WWARN Stories...

  • Home
  • Malaria Overview
  • Malaria Research
  • News
  • Videos
  • Blogs
  • Malaria Q&A
  • Events
  • Jobs
  • About Us
  • Board of Advisors
  • Contact

Copyright © 2025 Malaria.com ยท Log in